Status:
UNKNOWN
Hyp Obst Cardiomyopathy
Lead Sponsor:
Assiut University
Conditions:
Hypertrophic Obstructive Cardiomyopathy
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Hypertrophic Obstructive cardiomyopathy (HOCM) is the most common genetic cardiomyopathy, heterogeneous in phenotype and clinical course. The genotype-phenotype relationship and associated molecular m...
Detailed Description
Hypertrophic Obstructive cardiomyopathy (HOCM) is the most common genetic cardiomyopathy, heterogeneous in phenotype and clinical course. The genotype-phenotype relationship and associated molecular m...
Eligibility Criteria
Inclusion
- All patients that present with hypertrophic obstructive cardiomyopathy (HOCM) with mean pressure gradient\>50 mm Hg at rest or on provocation
- HOCM patients with severe mitral regurgitation.
- HOCM patients with New York Heart Association (NYHA) functional class II to IV despite optimal medical treatment consisting of -blocking agents, calcium channel blockers, or both.
Exclusion
- b. Exclusion criteria:
- Non-obstructive physiological characteristics.
- Previous MV surgery.
- Patient with intrinsic pathology of the mitral valve.
- Patients \<18 years.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT04329689
Start Date
May 1 2020
End Date
June 1 2022
Last Update
April 1 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.